8-KOther EventsExhibits & Filings

ALNYLAM PHARMACEUTICALS, INC. 8-K Report, Corporate Update (Dec 11, 2025)

Filed December 11, 2025For Securities:ALNY

Summary

Alnylam Pharmaceuticals, Inc. (ALNY) announced on December 11, 2025, that it has entered into agreements to repurchase approximately $34.4 million in aggregate principal amount of its 1.00% convertible senior notes due 2027. The total cost for this repurchase is approximately $51.9 million, including accrued interest. This action is expected to reduce the outstanding principal amount of these notes to approximately $362.8 million upon closing. This move suggests Alnylam is actively managing its debt obligations and capital structure. While the financial impact on the company's balance sheet and cash flow will be immediate, the forward-looking statements indicate potential risks related to execution of their strategy, drug development, regulatory approvals, and market performance. Investors should monitor the company's cash position and ongoing debt management strategies.

Key Highlights

  • 1Alnylam repurchased approximately $34.4 million of its 1.00% convertible senior notes due 2027.
  • 2The total cost for the repurchase is approximately $51.9 million, including accrued interest.
  • 3Following the repurchase, approximately $362.8 million in principal amount of these notes will remain outstanding.
  • 4The repurchase agreements were privately negotiated with certain noteholders.
  • 5The transaction's closing is subject to customary conditions and a measurement period for the final price adjustment.
  • 6Existing capped call transactions related to the notes are expected to remain in effect.

Frequently Asked Questions

The filing does not explicitly state the reason for the repurchase. However, companies typically undertake such actions to manage their debt, reduce future interest expenses, or adjust their capital structure. It could also be a strategic move to decrease dilution risk associated with convertible debt.

The repurchase will reduce the outstanding principal amount of convertible debt by $34.4 million and require a cash outflow of approximately $51.9 million. This will impact the company's cash reserves and debt-to-equity ratio. The exact impact on earnings will depend on the interest expense savings compared to the cash outlay.

No, the filing states that the capped call transactions previously entered into in connection with the issuance of the Notes are expected to remain in effect notwithstanding the repurchases.

The company highlights various risks, including challenges in executing its 'Alnylam P5x25' strategy, difficulties in drug discovery and development, obtaining regulatory approvals, manufacturing and supply chain issues, intellectual property protection, managing growth, and potential litigation or investigations.